BioAscent Discovery Limited has announced the appointments of Angus Morrison, PhD, as Director of Chemistry and Stuart McElroy, PhD, as Director of Biosciences, to oversee the development and delivery of BioAscent’s integrated drug discovery services.
Angus joins BioAscent from the European Screening Centre, Newhouse where, as head of chemistry, he was responsible for over 30 hit-to-lead programmes. Prior to this, Angus held leadership roles at Organon, Schering-Plough, MSD, Prosidion and Redx Oncology.
Stuart has extensive experience of developing and trouble-shooting novel screening assays, designing screening cascades, compound screening, hit validation and supporting hit-to-lead and lead optimisation programmes. Before joining BioAscent, Stuart was head of biology at the European Screening Centre, where he led a team of bioscientists in prosecuting and triaging the output of over 90 high throughput screens across all major target classes and disease indications. Previously Stuart helped establish the Dundee Drug Discovery Unit (DDU), working across a wide array of novel drug targets and assays in partnerships between the DDU and both large pharma and SMEs.